Univariable Cox proportional hazards regression model screening prognostic factors
| Impact factors | Univariable analysis | |
| p Value | 95% CI | |
| ECT2 expression | ||
| high vs low/loss | 0.000 | 0.185 to 0.485 |
| Age | ||
| ≤46 v s>46 | 0.360 | 0.721 to 1.852 |
| Tumour size (cm) | ||
| ≤2 vs >2 | 0.289 | 0.534 to 1.206 |
| Tumour type | ||
| Invasive ductal carcinoma vs invasive lobular carcinoma | 0.996 | 0.652 to 1.537 |
| Grade | ||
| High vs low | 0.304 | 0.818 to 1.896 |
| Lymph node metastasis | ||
| Yes vs no | 0.006 | 0.372 to 0.856 |
| TNM stages | ||
| I+II vs III+IV | 0.364 | 0.802 to 1.825 |
| Recurrence | ||
| Yes vs no | 0.212 | 0.501 to 1.167 |
| HER-2 | ||
| Positive vs negative | 0.381 | 0.784 to 1.829 |
| ER | ||
| Positive vs negative | 0.797 | 0.697 to 1.601 |
| PR | ||
| Positive vs negative | 0.984 | 0.667 to 1.513 |
| HER-2/ER/PR | ||
| Triple negative vs any one positive | 0.001 | 0.345 to 0.782 |
| Ki-67 proliferation index | ||
| ≥14 vs >14 | 0.041 | 1.016 to 2.608 |
| Menopause | ||
| Yes vs no | 0.542 | 0.754 to 1.712 |
ECT2, epithelial cell transforming sequence 2; HER-2, human epidermal growth factor 2; OR, oestrogen receptor; PR, progesterone receptor.